NCT04493554

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Jul 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 27, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

July 28, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 30, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2021

Completed
Last Updated

January 7, 2021

Status Verified

January 1, 2021

Enrollment Period

4 months

First QC Date

July 27, 2020

Last Update Submit

January 5, 2021

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

  • Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli

    Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions

    45 minutes - 100 minutes after treatment

  • Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli

    Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions

    45 minutes - 100 minutes after treatment

Secondary Outcomes (2)

  • Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions

    45 minutes - 100 minutes after treatment

  • Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions

    45 minutes - 100 minutes after treatment

Study Arms (2)

Vasopressin

EXPERIMENTAL

Vasopressin (20 IU) intranasally

Drug: Vasopressin

Placebo

PLACEBO COMPARATOR

Placebo intranasally

Drug: Placebo

Interventions

VasopressinDRUG

Administration of vasopressin (20 IU) intranasally

Vasopressin
PlaceboDRUG

Administration of placebo intranasally

Placebo

Eligibility Criteria

Age18 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy participants
  • Non smokers

You may not qualify if:

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment
  • Contra-indications for vasopressin
  • Contra-indications for eye-tracking data acquisition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, 611731, China

Location

MeSH Terms

Interventions

Vasopressins

Intervention Hierarchy (Ancestors)

Pituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteins

Study Officials

  • Keith Kendrick, PhD

    University of Electronic Science and Technology of China (UESTC)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 27, 2020

First Posted

July 30, 2020

Study Start

July 28, 2020

Primary Completion

November 30, 2020

Study Completion

January 1, 2021

Last Updated

January 7, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)